Optimizing the safety of antibody–drug conjugates for patients with solid tumours
Dana-Farber Brigham Cancer Center · Harvard University · +5 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
218
total citations
- FWCI
- 47.25
- Percentile
- 100%
- References
- 207
Citations per year
Authors
4- PTPaolo TarantinoCorresponding
Dana-Farber Brigham Cancer Center, Harvard University, Dana-Farber Cancer Institute, University of Milan
- BRBiagio Ricciuti
Harvard University, Dana-Farber Cancer Institute
- SPShan Pradhan
United States Food and Drug Administration, Center for Drug Evaluation and Research
- SMSara M. Tolaney
Dana-Farber Cancer Institute, Harvard University, Dana-Farber/Harvard Cancer Center, Dana-Farber Brigham Cancer Center
Topics & keywords
Topics
Keywords
- Medicine
- Tolerability
- Adverse effect
- Drug
- Clinical trial
- Intensive care medicine
- Oncology
- Pharmacology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.